All In Biotech

Drug Trial Radar · NCT03915431

A Study of NCS-01 in Patients With Acute Ischemic Stroke

A Phase 1/2 Randomized Study to Evaluate the Safety and Tolerability of Intracarotid Artery Administration of NCS-01 in Patients With Acute Ischemic Stroke

Last checked: Nov 19, 2026Latest source record: Sep 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

16

Planned (sponsor's estimate)

Start

Feb 27, 2020

Primary completion

Oct 2027

Study completion Oct 2028

Sponsor

Lead sponsor
NC Medial Research IncIndustry
Sponsor type
Industry
First posted
Apr 16, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an initial Phase1/2 dose-finding, randomized, multi-center study to evaluate the safety and tolerability of NCS-01 in patients with acute ischemic stroke. All patients will be randomized within 48 hours of stroke onset. This study will be conducted in 2 stages.

Conditions

  • Ischemic Stroke

Interventions

  • NCS-01Biological

    single infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with adverse events -Safety by Incidence of Treatment-Emergent Adverse EventsTime frame: multiple times for the duration of the study (baseline through Month 12)
  2. National Institutes of Health Stroke Scale (NIHSS)Time frame: 1 hour, 3 hours, and 6 hours post infusion
  3. Number of participants with change in in physical examinationTime frame: multiple times from baseline through Month 12
  4. Number of participants with change in Electrocardiography (ECG)Time frame: multiple times for the duration of the study (baseline through Month 12)
  5. Number of participants with change in clinical laboratory evaluationsTime frame: multiple times for the duration of the study (baseline through Month 12)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Miami

    Miami, Florida

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.